781 related articles for article (PubMed ID: 19093811)
1. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
2. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
5. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil.
Daher EF; Fonseca PP; Gerhard ES; Leitão TM; Silva Júnior GB
J Parasitol; 2009 Jun; 95(3):652-5. PubMed ID: 19642802
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
[TBL] [Abstract][Full Text] [Related]
7. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
Ali A
Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
[TBL] [Abstract][Full Text] [Related]
8. [Intestinal parasitic infections and leishmaniasis in patients with HIV infection].
Moreno-Camacho A; López-Vélez R; Muñoz Sanz A; Labarga-Echevarría P
Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():52-60. PubMed ID: 9859620
[TBL] [Abstract][Full Text] [Related]
9. [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].
Delgado Fernández M; García Ordoñez MA; Martos Pérez F; Reguera Iglesias JM; Jiménez Oñate F; Colmenero Castillo JD
An Med Interna; 1997 Oct; 14(10):506-10. PubMed ID: 9424140
[TBL] [Abstract][Full Text] [Related]
10. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
[TBL] [Abstract][Full Text] [Related]
12. [Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection].
Reus S; Sánchez R; Portilla J; Boix V; Priego M; Merino E; Román F
Enferm Infecc Microbiol Clin; 1999 Dec; 17(10):515-20. PubMed ID: 10650648
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
Borrelli P; Imperato A; Murdaca G; Scudeletti M
Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
[TBL] [Abstract][Full Text] [Related]
15. AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.
de Vallière S; Mary C; Joneberg JE; Rotman S; Bullani R; Greub G; Gillmore JD; Buffet PA; Tarr PE
Am J Trop Med Hyg; 2009 Aug; 81(2):209-12. PubMed ID: 19635871
[TBL] [Abstract][Full Text] [Related]
16. [Visceral leishmaniasis and HIV infection in the HAART era].
Marques N; Cabral S; Sá R; Coelho F; Oliveira J; Saraiva da Cunha JG; Meliço Silvestre A
Acta Med Port; 2007; 20(4):291-8. PubMed ID: 18198072
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
[TBL] [Abstract][Full Text] [Related]
18. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
19. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis.
d'Ettorre G; Ceccarelli G; Carnevalini M; Forcina G; Zaffiri L; Massetti AP; Mastroianni CM; Vullo V
Acta Trop; 2006 Aug; 99(1):83-7. PubMed ID: 16962979
[TBL] [Abstract][Full Text] [Related]
20. 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients.
Bourgeois N; Bastien P; Reynes J; Makinson A; Rouanet I; Lachaud L
HIV Med; 2010 Nov; 11(10):670-3. PubMed ID: 20500233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
